Investor FAQs


Spyre Therapeutics is headquartered at 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453.

Spyre Therapeutics is incorporated in the state of Delaware.

Spyre Therapeutics will end its fiscal year on December 31st.

Spyre Therapeutics trades on the NASDAQ stock exchange under the symbol “SYRE”.

Spyre Therapeutics’ transfer agent is Equiniti Trust Company, LLC.

Spyre Therapeutics’ auditor is PricewaterhouseCoopers LLP.

Spyre Therapeutics’ SEC filings can be viewed on our SEC Filings page or at (Search for Spyre Therapeutics, Inc., the “SYRE” company ticker, or for CIK: 1636282).

You can submit queries to Spyre Therapeutics’ investor relations department by contacting

Investor Contact
Investor Email Alerts
* Required Fields